摘要
目的:比较奥氮平与利培酮治疗精神活性物质所致精神障碍的疗效及安全性。方法:采用回顾性研究方法,收集180例精神活性物质所致精神障碍患者的临床资料,按照治疗药物不同分为对照组与观察组各90例。对照组予利培酮治疗;观察组予奥氮平治疗。采用阳性与阴性症状评定量表(PANSS)、血生化检测等评价其临床治疗效果及不良反应。结果:两组患者PANSS评分自治疗第2周末起,较治疗前明显下降(P<0.05);但两组间治疗后各时点比较,差异无统计学意义(P>0.05)。两组吸食不同精神活性物质患者PANSS总分自第2周末起已较治疗前明显下降(P<0.05),但治疗后各时点各亚组间PANSS总分及减分率比较,差异无统计学意义(P>0.05)。治疗后,两组间及各亚组间药品不良反应发生率比较,差异均无统计学意义(P>0.05);观察组三酰甘油与BMI增加值明显高于对照组(P<0.05)。结论:奥氮平与利培酮治疗精神活性物质致精神障碍者治疗效果相当,且均具有较高安全性。
Objeetlve:To compare the efficacy and safety of olanzapine and risperidone in the treatment of mental disorders caused by psychoactive substances. Methods:A retrospective analysis were used, 180 cases clinical data diag- nosed as psychoactive substance-induced mental disorders, were selected and divided into control group and observation group according to the different treatment, 90 cases each. The control group was treated with risperidone, observation group was olanzapine. The clinical curative effect and adverse drug reactions of two groups were evaluated by Positive and Nega- tive Symptom Assessment Scale (PANSS) and test of biochemical index. Results: In the first 2 weeks of treatment, the PANSS score of two groups decreased significantly than before ( P 〈 0.05 ). But there was no statistically significant at each time point after treatment between the two groups (P 〉 0.05 ). The PANSS total score of two group of patients who taking different psychoactive substances had significantly decreased from 'the 2 weeks' treatment than before treatment (P 〈 0.05 ), but there were no significant difference in the PANSS and reduction rate at each time point between each subgroup ( P 〉 0.05). After the treatment, there had no significant difference of adverse drug reactions between the two groups and each sub-group( P 〉 0.05 ) . The triglyceride value and increased BMI value of observation group were significantly higher than the control group ( P 〈 0.05 ). Conclusion : The treatment effect of olanzapine and risperidone in psychoactive substance-induced mental disorders showed equivalent and high security.
出处
《药物流行病学杂志》
CAS
2015年第9期533-536,共4页
Chinese Journal of Pharmacoepidemiology